<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Poster 327: Prostate Cancer Patient-Derived Xenograft Treatment Data

Evaluation of anti-androgen therapy in a panel of prostate patient-derived xenograft models

Jason Davies, Nektaria Papadopoulou, Louise Wainwright, Anthony Oakden, Chira Roberts, Jane Wrigley, Jason King, Anne Collins*, Wubin Qian, Likun Zhang, Bin Fan, Davy Ouyang, Jie Cai, and Rajendra Kumari
*University of York, York, UK

Poster 327: Prostate Cancer Patient-Derived Xenograft Treatment DataProstate cancer is a complex disease, with multiple stages that need to be accurately recapitulated in the preclinical setting. A lack of prostate cancer models which fully represent the benign, latent, aggressive, and metastatic forms of human disease has hampered preclinical research and new drug development.

Patient-derived xenografts (PDX) are known to be more clinically relevant than conventional cell line derived alternatives, providing a new preclinical modelling option. We have developed and validated a panel of prostate cancer PDX models for preclinical studies.

This poster details hormone sensitive and castrate resistant prostate cancer (CRPC) PDX model characterization by H&E staining, immunohistochemistry, and RNAseq, as well as standard of care and new hormonal agent treatment data.

Read this Poster to Discover:

  • A well characterized panel of hormone sensitive and CRPC prostate cancer PDX models for predictive preclinical drug development

  • That the PDX models retain the structure of parental tumours, and expression levels of AR and PSA

  • Varied response and resistance to docetaxel, enzalutamide, and abiraterone across the panel of prostate cancer PDX models

Download the Poster Now!

Download Now

Your privacy is important to us.
We'll never share your information.